Jci_page_head_homepage_01 Jci_page_head_homepage_02
Sunil Srivastava, M. Neale Weitzmann, Simone Cenci, F. Patrick Ross, Stuart Adler, Roberto Pacifici
Published in Volume 104, Issue 4
J Clin Invest. 1999; 104(4):503–513 doi:10.1172/JCI7094
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 9

(a) E2 decreases JNK activity in RAW 264.7 cells. RAW 264.7 cells were treated with either E2 or vehicle for 24 hours and then stimulated with IL-1 and TNF for 0–15 minutes. Cell extracts were then immunoprecipitated by anti-JNK antibody. Equal amounts of immunoprecipitation material were recovered and incubated with recombinant GST-c-Jun and [γ-32P]ATP. Phosphorylated material was resolved by SDS-PAGE and viewed by autoradiography. Representative data from 1 experiment. (b) E2 has no effects on total JNK levels. Western blot studies were conducted as described in the text using an antibody that recognizes the dephosphorylated and the phosphorylated species of both JNK1 and JNK2. Representative data from 1 of 3 experiments. (c) E2 decreases the level of phosphorylated (active JNK). Western blot analysis was conducted using cell lysates from control- and E2-treated RAW 264.7 cells stimulated with IL-1β and TNF for 5 minutes, and an antibody specific for phospho JNK. Representative data from 1 of 3 experiments.